Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15719MR)

This product GTTS-WQ15719MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15719MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4297MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ9948MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ8549MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ2856MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ2414MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ1844MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ4433MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ2009MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW